论文部分内容阅读
目的观察孟鲁司特钠对毛细支气管炎患儿临床症状及预后的影响。方法将106例毛细支气管炎患儿随机分为治疗组和对照组,两组均采用相同的综合治疗,治疗组在此基础上加用孟鲁司特钠4 mg每晚1次口服,对比两组的临床疗效。结果治疗组达到喘息缓解所需时间为(5.8±2.1)d,对照组为(8.6±3.7)d。治疗组住院时间为(7.8±1.6)d,对照组为(11.2±2.8)d。两组比较差异有统计学意义(P<0.01);随访3个月后,治疗组有4例(7.4%)出现再次喘息,而对照组有12例(23.1%)出现再次喘息。结论孟鲁司特钠能有效改善临床症状并缩短住院时间,降低毛细支气管炎患儿患病后喘息的复发率。
Objective To observe the impact of montelukast on the clinical symptoms and prognosis of children with bronchiolitis. Methods A total of 106 children with bronchiolitis were randomly divided into treatment group and control group. Both groups were treated with the same combination therapy. On the basis of the above treatment, the treatment group received Montelukast sodium 4 mg once a night orally, Group clinical efficacy. Results The time required to relieve wheezing was (5.8 ± 2.1) days in the treatment group and (8.6 ± 3.7) days in the control group. The hospitalization duration was (7.8 ± 1.6) days in the treatment group and (11.2 ± 2.8) days in the control group. There was a significant difference between the two groups (P <0.01). After 3 months of follow-up, four patients (7.4%) in the treatment group resumed wheezing, while 12 patients (23.1%) in the control group resumed wheezing. Conclusion Montelukast sodium can effectively improve the clinical symptoms and shorten the hospital stay and reduce the prevalence of wheezing recurrence in children with bronchiolitis.